A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Public ClinicalTrials.gov record NCT02963506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
Study identification
- NCT ID
- NCT02963506
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 303 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2016
- Primary completion
- Sep 30, 2017
- Completion
- Jul 31, 2018
- Last update posted
- Jun 5, 2023
2016 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| As0008 019 | Anniston | Alabama | 36207 | — |
| As0008 007 | La Jolla | California | 92037 | — |
| As0008 009 | Upland | California | 91786 | — |
| As0008 005 | Aventura | Florida | 33180 | — |
| As0008 022 | Ormond Beach | Florida | 32174-11 | — |
| As0008 030 | Sarasota | Florida | 34239 | — |
| As0008 027 | Boston | Massachusetts | 02111 | — |
| As0008 021 | Freehold | New Jersey | 07728 | — |
| As0008 015 | Cleveland | Ohio | 44109-19 | — |
| As0008 014 | Portland | Oregon | 97239 | — |
| As0008 001 | Duncansville | Pennsylvania | 16635 | — |
| As0008 020 | Austin | Texas | 78731 | — |
| As0008 006 | Dallas | Texas | 75231 | — |
| As0008 018 | Houston | Texas | 77030 | — |
| As0008 002 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02963506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2023 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02963506 live on ClinicalTrials.gov.